Analysis of the scope of indications and clinical application of Letermovir (Premin)

Letermovir is a new antiviral drug that mainly inhibits the activity of the human cytomegalovirus (CMV) DNA termination complex, thereby preventing viral replication and preventing and controlling infection. Clinically, letermovir is mainly used to prevent CMV infection in hematopoietic stem cell transplant (HSCT) recipients, especially for high-risk patients who are CMV seropositive but whose immune function has not yet recovered. Its effectiveness and safety have been verified by a large number of clinical studies.

In terms of scope of indications, letermovir is mainly targeted at adult hematopoietic stem cell transplant patients and is used to prevent infection in CMV seropositive individuals. Compared with traditional antiviral drugs, it has the characteristics of strong selectivity and low toxicity. It will not significantly affect bone marrow hematopoietic function, so it is safer to use in the early immunosuppressive state of transplantation. At the same time, some studies have also explored its potential application in kidney transplants and other immunosuppressed populations, but currently the main approved indications are still concentrated in HSCT patients.

In clinical application, letermovir can be administered via oral tablets or intravenous injection, and prophylactic medication is usually started from 0 to 28 days after transplantation. The dosage needs to be adjusted according to the patient's weight and liver function status. Studies have shown that use at standard doses can significantly reduce the incidence of CMV infection and related diseases. It is well tolerated and has a low incidence of adverse reactions, mostly mild to moderate gastrointestinal symptoms or mild elevations in serum enzymes.

Overall, letermovir has clear clinical value in preventing CMV infection, and is especially suitable for use in high-risk hematopoietic stem cell transplant patients. Its safety and specificity advantages make it a commonly used CMV preventive drug in clinical practice. During clinical use, individualized plans need to be designed based on the patient's individual risk, liver and kidney function, and immune status to achieve the best preventive effect and long-term safety.

Keyword tags: Letermovir, CMVPrevention, hematopoietic stem cell transplantation, anti-virus, safety

Reference materials:https://www.drugs.com/mtm/letermovir-oral-injection.html